• Beyond Air won FDA Breakthrough Device Designation for LungFit GO in nontuberculous mycobacterial pulmonary disease.
• Designation supports closer FDA engagement as the company finalizes a future NTM-PD clinical study design.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beyond Air Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310800PRIMZONEFULLFEED9818149) on August 31, 2026, and is solely responsible for the information contained therein.